136 related articles for article (PubMed ID: 3549083)
1. Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis.
Woo KT; Edmondson RP; Yap HK; Wu AY; Chiang GS; Lee EJ; Pwee HS; Lim CH
Clin Nephrol; 1987 Feb; 27(2):56-64. PubMed ID: 3549083
[TBL] [Abstract][Full Text] [Related]
2. Effects of triple therapy in IgA nephritis: a follow-up study 5 years later.
Woo KT; Lee GS; Lau YK; Chiang GS; Lim CH
Clin Nephrol; 1991 Aug; 36(2):60-6. PubMed ID: 1934661
[TBL] [Abstract][Full Text] [Related]
3. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial.
Walker RG; Yu SH; Owen JE; Kincaid-Smith P
Clin Nephrol; 1990 Sep; 34(3):103-7. PubMed ID: 2225560
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis.
Murphy BF; McDonald I; Fairley KF; Kincaid-Smith PS
Clin Nephrol; 1992 May; 37(5):229-34. PubMed ID: 1606772
[TBL] [Abstract][Full Text] [Related]
5. [Effect of ligustrazine on proliferative glomerulonephritis].
Tang X
Zhong Yao Cai; 2003 Aug; 26(8):611-2. PubMed ID: 14649206
[TBL] [Abstract][Full Text] [Related]
6. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
[TBL] [Abstract][Full Text] [Related]
7. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin.
Woo KT; Lee GS
Clin Nephrol; 1991 Apr; 35(4):184. PubMed ID: 1855324
[No Abstract] [Full Text] [Related]
8. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial.
Yoshikawa N; Honda M; Iijima K; Awazu M; Hattori S; Nakanishi K; Ito H;
Clin J Am Soc Nephrol; 2006 May; 1(3):511-7. PubMed ID: 17699253
[TBL] [Abstract][Full Text] [Related]
9. Controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephritis with renal impairment.
Lee GS; Woo KT; Lim CH
Clin Nephrol; 1989 May; 31(5):276. PubMed ID: 2661066
[No Abstract] [Full Text] [Related]
10. The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function.
Moriyama T; Honda K; Nitta K; Yumura W; Nihei H
Clin Exp Nephrol; 2004 Sep; 8(3):237-42. PubMed ID: 15480901
[TBL] [Abstract][Full Text] [Related]
11. Effect of combined immunosuppressive anticoagulant and antiplatelet therapy of the course of chronic mesangial-proliferative glomerulonephritis.
Matousovic K; Matl I; Zabka J; Zástava V; Rossmann P; Prát V
Czech Med; 1985; 8(3):151-7. PubMed ID: 3932033
[TBL] [Abstract][Full Text] [Related]
12. Benefit of cyclophosphamide therapy in IgA nephritis may have been obscured by warfarin-related nephropathy in the randomized trials in which warfarin and dipyridamole were used in combination with cyclophosphamide.
Brodsky SV; Rovin BH; Hebert LA
Nephrol Dial Transplant; 2012 Feb; 27(2):475-7. PubMed ID: 21948859
[No Abstract] [Full Text] [Related]
13. A case of IgA nephritis showing diffuse podocytic detachment from the glomerular basement membrane.
Moriya T; Nakazawa K; Itoh N; Shigematsu H; Higuchi M; Miyasaka M; Oguchi H
Nihon Jinzo Gakkai Shi; 1992 Apr; 34(4):423-30. PubMed ID: 1635288
[TBL] [Abstract][Full Text] [Related]
14. The effect of treatment with prednisolone or cyclophosphamide-warfarin-dipyridamole combination on the outcome of patients with membranous nephropathy.
Shearman JD; Yin ZG; Aarons I; Smith PS; Woodroffe AJ; Clarkson AR
Clin Nephrol; 1988 Dec; 30(6):320-9. PubMed ID: 3243041
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy using prednisolone and cyclophosphamide slows the progression of moderately advanced IgA nephropathy.
Tsuruya K; Harada A; Hirakata H; Mitsuiki K; Johko T; Kondoh H; Takechi S; Fujishima M
Clin Nephrol; 2000 Jan; 53(1):1-9. PubMed ID: 10661476
[TBL] [Abstract][Full Text] [Related]
16. [Long-term administration of cyclosporine A in patients with IgA nephropathy].
Chábová V; Tesar V; Zabka J; Rychlík I; Merta M; Jirsa M; Stejskalová A; Stejskal J
Cas Lek Cesk; 1996 Dec; 135(24):803-6. PubMed ID: 9072300
[TBL] [Abstract][Full Text] [Related]
17. Behcet's disease and IgA nephropathy: report of this association in a patient from Brazil and literature review.
Fernandes PF; Júnior GB; Barros FA; Sousa DC; Franco LM; Patrocínio RM
Invest Clin; 2006 Dec; 47(4):405-11. PubMed ID: 17176908
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive treatment of Berger's disease.
Faedda R; Pirisi M; Satta A; Bosincu L; Bartoli E
Clin Pharmacol Ther; 1996 Nov; 60(5):561-7. PubMed ID: 8941029
[TBL] [Abstract][Full Text] [Related]
19. Combined therapy in children and adolescents with IgA nephropathy.
Murakami K; Yoshioka K; Akano N; Takemura T; Okada M; Aya N; Hino S; Miyazato H; Yagi K; Maki S
Nihon Jinzo Gakkai Shi; 1994 Jan; 36(1):38-43. PubMed ID: 8107307
[TBL] [Abstract][Full Text] [Related]
20. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up.
Kanno Y; Okada H; Saruta T; Suzuki H
Clin Nephrol; 2000 Nov; 54(5):360-5. PubMed ID: 11105796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
